TrialMolecular cancer2025

Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial.

Darren Korbie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.